Asset profile
Olanzapine (Zyprexa)
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 26 direct rivals (same mechanism and indication), 0 same-class, 41 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Olanzapine (Zyprexa): this drug | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Fazaclo | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Iloperidone (PD Psychosis Use) (Fanapt) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Loxapine (Adasuve) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Lurasidone | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Milsaperidone (VHX-896) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Olanzapine (Zyprexa Relprevv) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone (Invega) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Erzofri) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Hafyera) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Sustenna) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Paliperidone Palmitate (Invega Trinza) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Perseris | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) |
…and 52 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
vs Asenapine · Schizophreniavs Clozapine · Schizophreniavs Iloperidone (PD psychosis use) · Schizophreniavs Loxapine (Adasuve) · Schizophreniavs Lurasidone · Schizophreniavs Milsaperidone (VHX-896) · Schizophrenia
20 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(28 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (7)
October 2026 (2)
November 2026 (1)
Phase 3Misuse, OpioidActive not recruiting
Est. primary completion 2026-11-01 · NCT06200181 · CT.gov ↗
What to watch
December 2026 (4)
Phase 2Anorexia Nervosa with Significantly Low Body WeightEnrolling by invitation
Est. primary completion 2026-12 · NCT05170919 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06554613 · CT.gov ↗
What to watch
Phase 3Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, OncologyRecruiting
Est. primary completion 2026-12-28 · NCT07633236 · CT.gov ↗
What to watch
Phase 1/2Depression, SequestraRecruiting
Est. primary completion 2026-12-31 · NCT05814640 · CT.gov ↗
What to watch
2027 (16)
February 2027 (1)
Phase 1SchizophreniaActive not recruiting
Est. primary completion 2027-02-10 · NCT03781115 · CT.gov ↗
What to watch
March 2027 (1)
Phase 3Advanced Cancer, Olanzapine, Progression Free SurvivalRecruiting
Est. primary completion 2027-03-20 · NCT06338683 · CT.gov ↗
What to watch
May 2027 (1)
June 2027 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06-03 · NCT07455955 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma, Advanced Esophageal Carcinoma, Metastatic Esophageal Carcinoma …Recruiting
Est. primary completion 2027-06-30 · NCT05705492 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Germ Cell CancerNot yet recruiting
Est. primary completion 2027-08 · NCT07662200 · CT.gov ↗
What to watch
September 2027 (4)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2027-09 · NCT07413809 · CT.gov ↗
What to watch
Phase 3Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest SyndromeRecruiting
Est. primary completion 2027-09 · NCT05895838 · CT.gov ↗
What to watch
Early phase / not applicableOlanzapine, Breast Cancer, DexamethasoneRecruiting
Est. primary completion 2027-09-29 · NCT07743827 · CT.gov ↗
What to watch
Phase 4SchizophreniaRecruiting
Est. primary completion 2027-09-30 · NCT04478838 · CT.gov ↗
What to watch
October 2027 (2)
December 2027 (4)
Early phase / not applicableCoronary Artery Disease, Aortic Valve DiseaseRecruiting
Est. primary completion 2027-12 · NCT05635227 · CT.gov ↗
What to watch
Phase 4SchizophreniaActive not recruiting
Est. primary completion 2027-12-20 · NCT07047651 · CT.gov ↗
What to watch
Phase 3Nausea, VomitingRecruiting
Est. primary completion 2027-12-30 · NCT07208305 · CT.gov ↗
What to watch
2028 (3)
April 2028 (1)
Early phase / not applicableLung CancerNot yet recruiting
Est. primary completion 2028-04-30 · NCT07442890 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Gastric Adenocarcinoma, Gastric CancerNot yet recruiting
Est. primary completion 2028-09 · NCT07581405 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Cancer, Advanced Solid Tumors, MalnutritionNot yet recruiting
Est. primary completion 2028-10 · NCT07722806 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 2Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown PrimaryRecruiting
Est. primary completion 2030-11-15 · NCT06995508 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Phase 2SchizophreniaNot yet recruiting
Est. primary completion 2032-02-01 · NCT07152184 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.